CytoGenix To Present DNA Vaccine Data at the Biomedical Advanced Research and Development Authority Industry Day in Washington, D.C.

CytoGenix, Inc. (CYGX.OB) announced today that Dr. Yin Chen has been selected to give an oral presentation entitled, “Rapid Production of DNA Vaccines Using a Novel Cell-Free synDNA™ Technology” at the Biomedical Advanced Research and Development Authority (BARDA) Industry Day on August 3, 2007 in Washington, D.C. This event provides a forum for companies to demonstrate technological advances in bio-medical countermeasures to man made and naturally occurring threats such as pandemic influenza that will contribute to government programs such as BARDA, Project Bioshield and the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy for Chemical, Biological, Radiological and Nuclear Threats.

The BARDA Industry Day event follows a three day PHEMC workshop. CytoGenix will have an opportunity to meet with personnel from HHS and other government agencies to discuss HHS implementation of the HHS Pandemic Influenza Implementation Plan, the HHS PHEMCE Implementation Plan for Chemical, Biological, Radiological, and Nuclear Threats, the Project BioShield Act of 2004, and the new HHS program for Biomedical Advanced Research and Development.

Dr. Yin Chen, CytoGenix’s Chief Scientific Officer will present the results of CytoGenix’s work to develop DNA vaccines against avian flu and other pandemic or bioterror agents. The rapidity with which DNA vaccines can be produced and the flexibility of CytoGenix’s synDNA technology make this technology a valuable addition to the biodefense arsenal.

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA™ production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of therapeutic DNA inside the cell. CytoGenix currently holds 11 granted patents and about 49 international or US pending patent applications claiming methods and materials in connection with these platform technologies.